DDInter1702 DDInter298
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.
Sorafenib {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Carboplatin
Sorafenib {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Carboplatin
Sorafenib {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is associated with {v} (Disease) breast cancer
breast cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methotrexate
Methotrexate {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Sorafenib {u} (Compound) upregulates {v} (Gene) XBP1
XBP1 {u} (Gene) is associated with {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Capecitabine
Capecitabine {u} (Compound) causes {v} (Side Effect) Venous thrombosis
Venous thrombosis {u} (Side Effect) is caused by {v} (Compound) Carboplatin
Sorafenib {u} (Compound) downregulates {v} (Gene) BUB1B
BUB1B {u} (Gene) is associated with {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Sorafenib {u} (Compound) upregulates {v} (Gene) XBP1
XBP1 {u} (Gene) regulates {v} (Gene) NQO1
NQO1 {u} (Gene) is bound by {v} (Compound) Carboplatin
Sorafenib {u} (Compound) downregulates {v} (Gene) BUB1B
BUB1B {u} (Gene) regulates {v} (Gene) SLC31A1
SLC31A1 {u} (Gene) is bound by {v} (Compound) Carboplatin
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methotrexate
Methotrexate {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Carboplatin
Sorafenib (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Carboplatin (Compound)
Sorafenib (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Carboplatin (Compound)
Sorafenib (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is associated with breast cancer (Disease) and breast cancer (Disease) is treated by Carboplatin (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Carboplatin (Compound)
Sorafenib (Compound) upregulates XBP1 (Gene) and XBP1 (Gene) is associated with esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Carboplatin (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine and Capecitabine (Compound) causes Venous thrombosis (Side Effect) and Venous thrombosis (Side Effect) is caused by Carboplatin (Compound)
Sorafenib (Compound) downregulates BUB1B (Gene) and BUB1B (Gene) is associated with esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Carboplatin (Compound)
Sorafenib (Compound) upregulates XBP1 (Gene) and XBP1 (Gene) regulates NQO1 (Gene) and NQO1 (Gene) is bound by Carboplatin (Compound)
Sorafenib (Compound) downregulates BUB1B (Gene) and BUB1B (Gene) regulates SLC31A1 (Gene) and SLC31A1 (Gene) is bound by Carboplatin (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Carboplatin (Compound)